Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

ZyVersa Therapeutics, Inc. Common Stock (ZVSA)

Pharmaceutical Preparations

https://www.zyversa.com

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are 1) Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. 2) IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

217 W. MAIN STREET
SOMERVILLE, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/13/2022

Market Cap

2,892,041

Shares Outstanding

1,640,000

Weighted SO

1,643,297

Total Employees

N/A

Upcoming Earnings

08/19/2024

Similar Tickers

CNSP --.--%

EFTR --.--%

VECT --.--%

AVRO --.--%

IMMX --.--%

HEPA --.--%

VIRI --.--%

ZURA --.--%

Beta

0.6490

Last Div

0.0000

Range

2.61-79.8

Chg

-0.2100

Avg Vol

132361

Mkt Cap

2892041

Exch

NASDAQ

Country

US

Phone

754 231 1688

DCF Diff

1.7809

DCF

3.2091

Div Yield

0.0000

P/S

185.3872

EV Multiple

-0.2707

P/FV

0.2722

Div Yield %

0.0000

P/E

-0.1075

PEG

-0.0016

Payout

0.0000

Current Ratio

0.0642

Quick Ratio

0.0642

Cash Ratio

0.0120

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

166430.4342

CCC

-166430.4342

Gross Margin

-0.1692

Op Margin

-657.6614

Pretax Margin

-1437.0660

Net Margin

-1399.4476

Eff Tax Rate

0.0262

ROA

-1.1213

ROE

-1.7251

ROCE

-1.0828

NI/EBT

0.9738

EBT/EBIT

2.1851

EBIT/Rev

-657.6614

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

25.7689

CF/Debt

0.0000

Equity Multi

2.2586

Rec Turnover

0.0000

Pay Turnover

0.0022

Inv Turnover

0.0000

FA Turnover

9.0017

Asset Turnover

0.0008

OCF/Share

-11.2759

FCF/Share

-11.2759

Cash/Share

0.1431

OCF/Sales

-603.4894

FCF/OCF

1.0000

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

0.2722

P/B

0.2722

P/S

185.3872

P/E

-0.1075

P/FCF

-0.3072

P/OCF

-0.2492

P/CF

-0.2492

PEG

-0.0016

P/S

185.3872

EV Multiple

-0.2707

P/FV

0.2722

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Aug 09, 20:40 ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update GlobeNewswire Inc. Jan 17, 07:52 ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis GlobeNewswire Inc. Jan 04, 07:50 ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets Benzinga Dec 19, 13:34 Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session GlobeNewswire Inc. Dec 07, 11:20 ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes GlobeNewswire Inc. Dec 06, 21:00 ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering GlobeNewswire Inc. Dec 06, 21:00 ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering GlobeNewswire Inc. Dec 06, 21:00 ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering GlobeNewswire Inc. Dec 06, 21:00 ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering GlobeNewswire Inc. Dec 06, 07:20 ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways GlobeNewswire Inc. Nov 14, 16:35 ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results GlobeNewswire Inc. Nov 09, 07:35 ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model GlobeNewswire Inc. Oct 25, 06:50 ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease

Revenue Product Segmentation